Quality Statement

Pacific Biosciences is committed to providing high-quality products that meet customer expectations and comply with regulations. We will achieve these goals by adhering to and maintaining an effective quality-management system designed to ensure product quality, performance, and safety.


Image Use Agreement

By downloading, copying, or making any use of the images located on this website (“Site”) you acknowledge that you have read and understand, and agree to, the terms of this Image Usage Agreement, as well as the terms provided on the Legal Notices webpage, which together govern your use of the images as provided below. If you do not agree to such terms, do not download, copy or use the images in any way, unless you have written permission signed by an authorized Pacific Biosciences representative.

Subject to the terms of this Agreement and the terms provided on the Legal Notices webpage (to the extent they do not conflict with the terms of this Agreement), you may use the images on the Site solely for (a) editorial use by press and/or industry analysts, (b) in connection with a normal, peer-reviewed, scientific publication, book or presentation, or the like. You may not alter or modify any image, in whole or in part, for any reason. You may not use any image in a manner that misrepresents the associated Pacific Biosciences product, service or technology or any associated characteristics, data, or properties thereof. You also may not use any image in a manner that denotes some representation or warranty (express, implied or statutory) from Pacific Biosciences of the product, service or technology. The rights granted by this Agreement are personal to you and are not transferable by you to another party.

You, and not Pacific Biosciences, are responsible for your use of the images. You acknowledge and agree that any misuse of the images or breach of this Agreement will cause Pacific Biosciences irreparable harm. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. You must include any copyright notice originally included with the images on all copies.


You agree that Pacific Biosciences may terminate your access to and use of the images located on the PacificBiosciences.com website at any time and without prior notice, if it considers you to have violated any of the terms of this Image Use Agreement. You agree to indemnify, defend and hold harmless Pacific Biosciences, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Site from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of the terms of this Image Use Agreement or Pacific Biosciences' termination of your access to or use of the Site. Termination will not affect Pacific Biosciences' rights or your obligations which accrued before the termination.

I have read and understand, and agree to, the Image Usage Agreement.

I disagree and would like to return to the Pacific Biosciences home page.

Pacific Biosciences

Pacific Biosciences of California, Inc. Announces Third Quarter 2018 Financial Results

Thursday, November 1, 2018

MENLO PARK, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its third quarter ended September 30, 2018.

Total revenue for the third quarter of 2018 was $18.2 million, compared to $23.5 million for the third quarter of 2017, primarily driven by lower instrument shipments and consumables sales.  Lower consumable sales were due to lower demand of PacBio RS II consumables and variation in customer ordering patterns.  Despite lower consumable sales, usage of installed Sequel instruments increased significantly during  the third quarter of 2018 compared with the third quarter of 2017.

Gross profit for the third quarter of 2018 was $3.2 million, resulting in a gross margin of 17.6%. Gross profit for the third quarter of 2017 was $8.2 million, resulting in a gross margin of 34.9%. Gross profit for the three-month period ended September 30, 2018 was negatively impacted by $2.4 million of product transition costs. In addition, lower manufacturing output during the three-month period ended September 30, 2018 also negatively impacted gross profit as a larger portion of manufacturing fixed costs was reflected in cost of sales for the period.

Operating expenses for the third quarter of 2018 totaled $27.9 million, compared to $29.8 million for the third quarter of 2017. Operating expenses for the third quarter of 2018 and 2017 included non-cash stock-based compensation of $4.5 million and $4.4 million, respectively.

Net loss for the third quarter of 2018 was $25.0 million, compared to $22.0 million for the third quarter of 2017.

Cash, cash equivalents and investments, excluding restricted cash, at September 30, 2018 totaled $115.7 million, compared to $62.9 million at December 31, 2017. The Company received $64.9 million in net proceeds excluding offering expenses from a public offering of common stock in September 2018. Excluding the above net proceeds of $64.9 million collected from our public offering, our cash burn in the third quarter of 2018 was approximately $12.6 million, compared with approximately $15.7 million in the second quarter of 2018.

Commenting on the third quarter results, Mike Hunkapiller, Chairman and CEO of PacBio noted, “Some of our customers held back in purchasing products during the third quarter in anticipation of the new products we recently launched or have announced we are planning to launch early next year.  However, we have been very pleased with the enthusiastic response from our customers on the launch of our new 3.0 chemistry and 6.0 software in October.  We are also looking forward to the launch of our new 8M SMRT Cell and platform, with early access scheduled to begin during the first quarter of 2019.  We are also excited to announce the proposed merger with Illumina, which we believe will enable the combined company to provide SMRT Sequencing to a broader range of customers and at a much faster rate than we could have accomplished on our own.”

Conference Call Information

The Company will not be hosting a separate conference call to discuss its third quarter ending September 30, 2018 results.  A joint conference call with Illumina will be hosted at 5:00 p.m. Eastern Time.  Interested parties may listen to the call by 1.800.708.4540 toll free in the US, or 1.847.619.6397, using Conference ID # 47821173.

About Pacific Biosciences

Pacific Biosciences of California, Inc. (NASDAQ: PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) Technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing.  More information is available at www.pacb.com

Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the timeline for Pacific Biosciences’ potential development and commercialization of products, future uses, quality or performance of, or benefits of using, products or technologies, the proposed merger with Illumina and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.

Trevin Rard

Pacific Biosciences of California, Inc.
Unaudited Condensed Consolidated Statement of Operations
(amounts in thousands, except per share amounts)

Three Months Ended September 30, Nine Months Ended September 30,
2018   2017 2018   2017
Product revenue $  15,150 $  20,343 $  49,917 $  58,185
Service and other revenue  3,010  3,202  9,183  10,348
Total revenue  18,160  23,545  59,100  68,533
Cost of Revenue:
Cost of product revenue  12,250  11,547  31,127  31,064
Cost of service and other revenue  2,718  3,771  8,623  12,304
Total cost of revenue    14,968    15,318    39,750    43,368
Gross profit  3,192  8,227  19,350  25,165
Operating Expense:
Research and development  14,356  15,844  46,331  49,698
Sales, general and administrative  13,506  13,952  43,383  44,722
Total operating expense  27,862  29,796  89,714  94,420
Operating loss  (24,670 )  (21,569 )  (70,364 )  (69,255 )
Interest expense  (616 )  (633 )  (1,795 )  (2,297 )
Other income, net  242  181  396  125
Net loss $  (25,044 ) $  (22,021 ) $  (71,763 ) $  (71,427 )
Basic and diluted net loss per share $  (0.19 ) $  (0.19 ) $  (0.55 ) $  (0.70 )
Shares used in computing basic and diluted net loss per share  135,130  115,771  130,302  102,117

Pacific Biosciences of California, Inc.
Unaudited Condensed Consolidated Balance Sheets
(amounts in thousands)

September 30,   December 31,
2018   2017
Cash and investments $  115,747 $  62,872
Accounts receivable  6,404  13,433
Inventory  19,694  23,065
Prepaid and other current assets  2,028  2,249
Property and equipment  34,490  37,920
Long-term restricted cash  4,500  4,500
Other long-term Assets  43  45
Total Assets $  182,906 $  144,084
Liabilities and Stockholders’ Equity
Accounts payable $  5,966 $  9,093
Accrued expenses  9,298  12,618
Deferred service revenue  6,756  7,394
Deferred rent  13,949  14,453
Other liabilities  645  605
Financing derivative  28  183
Notes payable  14,384  13,635
Stockholders’ equity  131,880  86,103
Total Liabilities and Stockholders’ Equity $  182,906 $  144,084

Pacific Biosciences logo

Source: Pacific Biosciences of California, Inc.

Press Release

PacBio Grants Equity Incentive Award to New Employee

Friday, January 14, 2022


Visit our blog »